A One-Time Gene Edit Kept Cholesterol Down for a Year. Here's What the Data Can and Can't Say.

A one-time infusion that edits a cholesterol-controlling gene kept LDL levels down a full year after treatment, according to new data from a 15-person Phase 1a trial run by CRISPR Therapeutics and the Cleveland Clinic. The results, published simultaneously in the New England Journal of Medicine and presented at the European Society of Cardiology Congress in late August, mark a durability follow-up to an initial readout the same team published in November 2025.

The drug, CTX310, uses CRISPR-Cas9 to permanently disable ANGPTL3, a gene that makes a protein blocking the breakdown of LDL and triglycerides in the liver. At the highest dose tested, 0.1 to 0.8 mg per kilogram delivered as a single IV infusion, patients saw average one-year reductions of 53% in LDL and 48% in triglycerides, with the strongest responders dropping as much as 84% and 78% respectively. No treatment-related serious side effects or major liver enzyme changes were reported.

The trial is small enough that those numbers deserve context before they shape any decision. Only 15 patients across four dyslipidemia categories were enrolled, and the standout figures come from just four people at the top dose. This is a Phase 1a dose-finding and safety study, not a trial designed to measure whether the treatment prevents heart attacks or strokes, and that kind of outcomes data, along with a Phase 2 or 3 program, is still years off.

Dr. Steven Nissen of the Cleveland Clinic, the trial's lead investigator, framed the appeal less around the percentage drops than around a persistent problem in cardiology: getting people to keep taking their pills. "Half of the patients who are treated with cholesterol-lowering drugs stop taking them within a year," he said, calling the one-time approach spectacular and "the door to the future." That framing is the real news hook here, a treatment aimed at the adherence gap rather than at outperforming existing drugs on potency alone.

ANGPTL3 was not a random target. Researchers identified it after studying people with naturally occurring loss-of-function mutations in the gene, who live with lifelong low LDL and triglycerides and are protected from coronary artery disease, a pattern described in a 2017 NEJM genetics study. An antibody drug against the same target, evinacumab (Evkeeza), was already FDA-approved in 2021 for severe familial hypercholesterolemia, though it requires repeat infusions rather than a single dose.

CTX310 is not the only gene-editing approach racing toward market. Verve Therapeutics, backed by Eli Lilly, published Phase 1b data in NEJM in May 2026 for VERVE-102, a base-editing drug that targets a different gene, PCSK9, and reduced LDL by up to 62% in 14 patients. The two programs represent competing editing techniques and gene targets aimed at the same one-and-done pitch, and neither has yet been tested at the scale needed to compare them head to head.

Dr. Eric Topol of Scripps Research has urged caution about how far ahead of the data that pitch has run, describing the idea of an inexpensive, one-and-done treatment as "a fantasy" for now, given that gene editing remains expensive and its long-term safety is still unclear. That caution carries particular weight here because a CRISPR edit cannot be undone. If a safety issue emerges years later, there is no way to reverse the change, which is why the FDA has recommended long-term follow-up, historically running as long as 15 years, for gene-editing therapies.

Cost is the other open question hovering over any future approval. The only CRISPR therapy on the market so far, Casgevy, treats sickle cell disease and beta thalassemia and carries a price tag of about $2.2 million per patient, a figure that gives some shape to what a commercial version of CTX310 or VERVE-102 might eventually cost a health system, long before either drug reaches the pharmacy.